Stock Chart

AGIO

$32.82 +3.34%
Score: 43.7 HOLD
LEAPs: SELL $40
i
LEAPs Option Signal

Type: SELL wallstreet
Strike: $40
Premium: $3.00
Expiry: Jan 15, 2027
Target: $40
Score: -100

LEAPs are long-term options (1+ year) with less time decay.
Pro
Screener
Vol: 0.64x (vs SPY: 0.8x | vs QQQ: 0.8x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Nov 11, 2026
Bear Pennant weak / forming — below our quality gate quality 50/100
A Bear Pennant is taking shape but hasn't passed our quality gate (60/100), so no projected path or levels are shown — only the forming rails on the chart below.
Historically breaks down 70% of the time (n=1,730). Measured-move targets failed our backtest — none shown.
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About AGIO - Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated …

Key Statistics

Market Cap $2B

This AGIO stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track AGIO's price movements with trendlines, gamma walls, and key support/resistance levels.